Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153096 | 0.73 | PIK3CD (0.32) | CYP3A4MAPK1 | |
| SCHEMBL17813550 | 0.69 | HSD17B10 (0.33) | HSD17B10CYP1A2KMT2AALDH1A1USP2 | |
| SCHEMBL17813546 | 0.68 | KAT2B (0.37) | HSD17B10HPGDHTTKMT2A | |
| SCHEMBL17813551 | 0.68 | TKT (0.32) | HSD17B10HPGDCYP1A2KMT2AALDH1A1 | |
| SCHEMBL17813502 | 0.67 | CYP1A2 (0.44) | HSD17B10HPGDHTTCYP1A2KMT2A | |
| SCHEMBL17813477 | 0.66 | CYP1A2 (0.46) | HSD17B10HPGDCYP1A2KMT2AALDH1A1 | |
| SCHEMBL5448218 | 0.66 | ALDH1A1 (0.53) | HSD17B10HPGDHTTKMT2AALDH1A1 | |
| SCHEMBL5445042 | 0.64 | KDM4E (0.56) | HSD17B10HPGDHTTKMT2AALDH1A1 | |
| SCHEMBL17813483 | 0.64 | LMNA (0.45) | HPGDCYP1A2KMT2AALDH1A1MEN1 | |
| SCHEMBL17813547 | 0.64 | HSD17B10 (0.35) | HSD17B10HPGDHTTCYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | HSD17B10 2464/4885HPGD 3222/4885HTT 1647/4885 |
| US-20160159801-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | HSD17B10 2464/4885HPGD 3222/4885HTT 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.